OpenLB
Open Library of Bioscience
Advanced Search
Iranian journal of basic medical sciences
Nov, 2017;20 (11): 1242-1249.

The role of TSG-6 and uroplakin III in bladder pain syndrome/ interstitial cystitis in rats and humans.

Yi-Song Lv, Rui Gao, Qing-Ming Lin, Tao Jiang, Qin Chen, Song-Xi Tang, Hou-Ping Mao, Hui-Liang Zhou, Lin-Sheng Cao
Author Information
  1. Yi-Song Lv: Department of Urology, The First Affiliated Hospital of Fujian Medical University, Fuzhou 350005, China.
  2. Rui Gao: Department of Urology, The First Affiliated Hospital of Fujian Medical University, Fuzhou 350005, China.
  3. Qing-Ming Lin: Department of Emergency Medicine, Fujian Provincial Hospital, Fuzhou 350005, China.
  4. Tao Jiang: Department of Urology, The First Affiliated Hospital of Fujian Medical University, Fuzhou 350005, China.
  5. Qin Chen: Department of Urology, The First Affiliated Hospital of Fujian Medical University, Fuzhou 350005, China.
  6. Song-Xi Tang: Department of Urology, The First Affiliated Hospital of Fujian Medical University, Fuzhou 350005, China.
  7. Hou-Ping Mao: Department of Urology, The First Affiliated Hospital of Fujian Medical University, Fuzhou 350005, China.
  8. Hui-Liang Zhou: Department of Urology, The First Affiliated Hospital of Fujian Medical University, Fuzhou 350005, China.
  9. Lin-Sheng Cao: Department of Urology, The First Affiliated Hospital of Fujian Medical University, Fuzhou 350005, China.
PMID: 29299202 DOI: 10.22038/IJBMS.2017.9540

Abstract

OBJECTIVES: We investigated the relationship between the expression of tumor necrosis factor-inducible gene 6 (TSG-6) with inflammation and integrity of the bladder epithelium in the bladder tissues of patients with bladder pain syndrome/interstitial cystitis (BPS/IC) and the mechanism of action using a rat model of BPS/IC.
MATERIALS AND METHODS: Expression of TSG-6 and uroplakin III was determined by immuno- histochemistry of bladder biopsy samples from control human subjects and patients with verified BPS/IC. Our rat model of BPS/IC was employed to measure the perfusion of bladders with hyaluronidase, and assessment of the effect of TSG-6 administration on disease progression. Treatment effects were assessed by measurement of metabolic characteristics, RT-PCR of TGR-6 and interleukin-6, bladder histomorphology, and immunohistochemistry of TGR-6 and uroplakin III.
RESULTS: The bladders of patients with BPS/IC had lower expression of uroplakin III and higher expression of TSG-6 than controls. Rats treated with hyaluronidase for 1 week developed the typical signs and symptoms of BPS/IC, and rats treated with hyaluronidase for 4 weeks had more serious disease. Administration of TSG-6 reversed the effects of hyaluronidase and protected against disease progression.
CONCLUSION: Our results indicate that TSG-6 plays an important role in maintaining the integrity of the bladder epithelial barrier.

Keywords

Bladder pain syndrome/-interstitial cystitis Immunofluorescence – staining Interleukin-6 TSG-6 Uroplakin III

References

  1. J Urol. 2004 Apr;171(4):1554-8 [PMID: 15017219]
  2. Am J Pathol. 2001 Nov;159(5):1711-21 [PMID: 11696432]
  3. Stem Cells. 2011 Oct;29(10):1572-9 [PMID: 21837654]
  4. Am J Physiol Lung Cell Mol Physiol. 2014 Jan;306(2):L120-31 [PMID: 24242012]
  5. Int J Urol. 2006 Apr;13(4):409-14 [PMID: 16734860]
  6. Biochem Soc Trans. 2006 Jun;34(Pt 3):446-50 [PMID: 16709183]
  7. Clin Drug Investig. 2013 Oct;33(10):737-42 [PMID: 23921624]
  8. Proc Natl Acad Sci U S A. 2010 Sep 28;107(39):16875-80 [PMID: 20837529]
  9. Neurobiol Dis. 2013 Nov;59:86-99 [PMID: 23851308]
  10. Neurourol Urodyn. 2013 Jan;32(1):9-18 [PMID: 22782909]
  11. Int J Urol. 2014 Jun;21(6):601-7 [PMID: 24286489]
  12. Int J Urol. 2013 Oct;20(10):1017-22 [PMID: 23379983]
  13. Int Urogynecol J. 2012 Dec;23(12):1715-20 [PMID: 22576327]
  14. Stem Cells. 2013 Oct;31(10):2042-6 [PMID: 23681848]
  15. Acta Pharmacol Sin. 2013 Jun;34(6):784-92 [PMID: 23474707]
  16. Can Urol Assoc J. 2014 Sep;8(9-10):E610-4 [PMID: 25295131]
  17. Cell Stem Cell. 2009 Jul 2;5(1):54-63 [PMID: 19570514]
  18. Int J Urol. 2009 Jul;16(7):597-615 [PMID: 19548999]
  19. Pharmacoeconomics. 2006;24(1):55-65 [PMID: 16445303]
  20. BMC Urol. 2012 Jun 08;12:17 [PMID: 22682521]
  21. J Cell Biol. 1992 Jan;116(2):545-57 [PMID: 1730767]
  22. BJU Int. 2008 Nov;102(10):1472-6 [PMID: 18410434]
  23. J Urol. 2008 Oct;180(4):1527-31 [PMID: 18710775]
  24. J Biol Chem. 2011 Jul 1;286(26):23559-69 [PMID: 21566135]
  25. J Biol Chem. 2013 Jan 4;288(1):423-31 [PMID: 23129777]
  26. Int J Urol. 2013 Nov;20(11):1118-22 [PMID: 23432185]
  27. Invest Ophthalmol Vis Sci. 2012 Mar 15;53(3):1372-80 [PMID: 22297496]
  28. J Control Release. 2010 Dec 1;148(2):147-59 [PMID: 20831887]
  29. J Neuroinflammation. 2012 Mar 27;9:59 [PMID: 22452753]
  30. World J Urol. 2012 Aug;30(4):457-64 [PMID: 22057291]
  31. Int Urogynecol J. 2011 Apr;22(4):395-400 [PMID: 20811877]
  32. J Neuroinflammation. 2014 Aug 04;11:135 [PMID: 25088370]
  33. J Cell Sci. 2003 May 15;116(Pt 10):1863-73 [PMID: 12692188]
  34. Stem Cell Res Ther. 2011 May 13;2(3):27 [PMID: 21569482]
Journal Article

Word Cloud

Created with Highcharts 10.0.0TSG-6bladderBPS/ICIIIuroplakinhyaluronidaseexpressionpatientspaincystitisdiseaseintegrityratmodelbladdersprogressioneffectsTGR-6treatedratsroleOBJECTIVES:investigatedrelationshiptumornecrosisfactor-induciblegene6inflammationepitheliumtissuessyndrome/interstitialmechanismactionusingMATERIALSANDMETHODS:Expressiondeterminedimmuno-histochemistrybiopsysamplescontrolhumansubjectsverifiedemployedmeasureperfusionassessmenteffectadministrationTreatmentassessedmeasurementmetaboliccharacteristicsRT-PCRinterleukin-6histomorphologyimmunohistochemistryRESULTS:lowerhighercontrolsRats1weekdevelopedtypicalsignssymptoms4weeksseriousAdministrationreversedprotectedCONCLUSION:resultsindicateplaysimportantmaintainingepithelialbarriersyndrome/interstitialhumansBladdersyndrome/-interstitialImmunofluorescence–stainingInterleukin-6Uroplakin

Similar Articles

Cited By